<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">With these results in mind, it is tempting to speculate that PD presents genetically as more of a systemic disorder, with a bias to brain pathology, as opposed to a primary brain disorder. In support of this view, PD-associated risk variants have been found associated with monocytes and the innate immune system,
 <sup>
  <xref ref-type="bibr" rid="CR13">13</xref>,
  <xref ref-type="bibr" rid="CR26">26</xref>,
  <xref ref-type="bibr" rid="CR48">48</xref>
 </sup> in addition to lymphocytes, mesendoderm, liver- and fat-cells.
 <sup>
  <xref ref-type="bibr" rid="CR49">49</xref>
 </sup> Recent work has also demonstrated a causal relationship between BMI and PD,
 <sup>
  <xref ref-type="bibr" rid="CR50">50</xref>
 </sup> which together with the re-purposing of exenatide (a glucagon-like peptide-1 receptor agonist currently licensed for the treatment of type 2 diabetes) for the potential treatment of PD,
 <sup>
  <xref ref-type="bibr" rid="CR51">51</xref>
 </sup> highlights the need to look beyond the brain and selective neuronal vulnerability.
</p>
